Search results for " cytotoxicity"

showing 10 items of 114 documents

Altered distribution and function of splenic innate lymphoid cells in adult chronic immune thrombocytopenia

2018

IF 7.607; International audience; Innate lymphoid cells (ILCs) have been characterized as innate immune cells capable to modulate the immune response in the mucosae. Human ILCs have been rarely described in secondary lymphoid organs except in tonsils. Moreover, their function and phenotype in human secondary lymphoid organs during autoimmune diseases have never been studied. We took advantage of splenectomy as a treatment of immune thrombocytopenia (ITP) to describe and compare splenic ILC from 18 ITP patients to 11 controls. We first confirmed that ILC3 represented the most abundant ILC subset in human non-inflamed spleens, accounting for 90% of total ILC, and that they were mostly constit…

0301 basic medicineAdultMalemedicine.medical_treatmentImmunologySplenectomyGene ExpressionSpleenInnate lymphoid cells[SDV.CAN]Life Sciences [q-bio]/Cancer03 medical and health sciencesInterferon-gamma0302 clinical medicineImmune systemhemic and lymphatic diseasesmedicineImmunology and AllergyHumansLymphocyte CountLymphocytesskin and connective tissue diseasesAutoimmune diseasePurpura Thrombocytopenic IdiopathicInnate immune systemNatural Cytotoxicity Triggering Receptor 2business.industryMacrophagesInnate lymphoid cellInterleukin-2 Receptor alpha SubunitGranulocyte-Macrophage Colony-Stimulating FactorCell DifferentiationMiddle Agedmedicine.diseasePathophysiologyImmunity Innate3. Good healthImmune thrombocytopenia030104 developmental biologymedicine.anatomical_structureLymphatic systemCase-Control StudiesImmunologySplenectomyFemalebusinessSpleen030215 immunology
researchProduct

Abstract 882: The anti-claudin 6 antibody, IMAB027, induces antibody-dependent cellular and complement-dependent cytotoxicity in claudin 6-expressing…

2018

Abstract Background Claudin 6 (CLDN6) is a tight junction membrane protein whose expression in normal tissue is confined to embryonic cells, but aberrantly expressed in various human cancer types, including some with a high medical need (eg, ovarian and uterine cancers). This tumor-specific expression in adult organs makes CLDN6 an attractive drug target; as such, IMAB027, an anti-CLDN6 monoclonal antibody (mAb), was developed. This report describes the preclinical characteristics of IMAB027. Methods IMAB027 was generated by hybridoma technology; the discovery process was set up so that mAbs that were good binders as well as inducers of the immune effector mechanisms of antibody-dependent c…

0301 basic medicineAntibody-dependent cell-mediated cytotoxicityCancer ResearchbiologyChemistryCancermedicine.diseaseComplement-dependent cytotoxicity03 medical and health sciences030104 developmental biology0302 clinical medicineOncologyCell cultureIn vivo030220 oncology & carcinogenesisCancer cellCancer researchmedicinebiology.proteinAntibodyCytotoxicityCancer Research
researchProduct

The Stalk Domain of NKp30 Contributes to Ligand Binding and Signaling of a Preassembled NKp30-CD3ζ Complex

2016

The natural cytotoxicity receptor (NCR) NKp30 (CD337) is a key player for NK cell immunosurveillance of infections and cancer. The molecular details of ligand recognition and its connection to CD3ζ signaling remain unsolved. Here, we show that the stalk domain (129KEHPQLGAGTVLLLR143) of NKp30 is very sensitive to sequence alterations, as mutations lead to impaired ligand binding and/or signaling capacity. Surprisingly, the stalk domains of NKp30 and NKp46, another NCR employing CD3ζ for signaling, were not exchangeable without drastic deficiencies in folding, plasma membrane targeting, and/or ligand-induced receptor signaling. Further mutational studies, N-glycosylation mapping, and plasma …

0301 basic medicineCell signalingCD3 ComplexImmunologyProtein domainBiologyCD3 ComplexBiochemistryCell membraneMice03 medical and health sciencesProtein DomainsCell surface receptormedicineAnimalsHumansMolecular BiologyNatural Cytotoxicity Triggering Receptor 3Natural Cytotoxicity Triggering Receptor 1Cell MembraneCell BiologyLigand (biochemistry)Cell biology030104 developmental biologymedicine.anatomical_structureMembrane proteinBiochemistrySignal transductionHeLa CellsSignal TransductionJournal of Biological Chemistry
researchProduct

A murine intestinal intraepithelial NKp46-negative innate lymphoid cell population characterized by group 1 properties

2017

The Ly49E receptor is preferentially expressed on murine innate-like lymphocytes, such as epidermal Vγ3 T cells, intestinal intraepithelial CD8αα(+) T lymphocytes, and CD49a(+) liver natural killer (NK) cells. As the latter have recently been shown to be distinct from conventional NK cells and have innate lymphoid cell type 1 (ILC1) properties, we investigated Ly49E expression on intestinal ILC populations. Here, we show that Ly49E expression is very low on known ILC populations, but it can be used to define a previously unrecognized intraepithelial innate lymphoid population. This Ly49E-positive population is negative for NKp46 and CD8αα, expresses CD49a and CD103, and requires T-bet expre…

0301 basic medicineCytotoxicity ImmunologicSUBSETSROR-GAMMA-TLYMPHOCYTESILC1TranscriptomeMice0302 clinical medicineInterferonNKp46-negativeMedicine and Health SciencesAntigens LyInterferon gammaLymphocytesIFN-γlcsh:QH301-705.5education.field_of_studyintestinalIFN-GAMMAInnate lymphoid cellNATURAL-KILLERIntestinesKiller Cells NaturalPhenotypeDIFFERENTIATIONSignal transductionNK Cell Lectin-Like Receptor Subfamily Amedicine.drugSignal TransductionintraepithelialEXPRESSIONPopulationNKP46(+) CELLSBiologyGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesInterferon-gammaImmunityAntigens CDmedicineAnimalseducationCell ShapeNatural Cytotoxicity Triggering Receptor 1INHIBITORY RECEPTORSBiology and Life SciencesEpithelial CellsMolecular biologyImmunity InnateNK-CELLS030104 developmental biologyNatural Cytotoxicity Triggering Receptor 1lcsh:Biology (General)ImmunologyTranscriptomeLy49E030215 immunologyTranscription Factors
researchProduct

Association between γ marker, human leucocyte antigens and killer immunoglobulin‐like receptors and the natural course of human cytomegalovirus infec…

2017

Natural killer (NK) cells provide a major defence against cytomegalovirus (HCMV) infection through the interaction of their surface receptors, including the activating and inhibitory killer immunoglobulin-like receptors (KIRs), and human leukocyte antigens (HLA) class I molecules. Also GM allotypes, able to influence the NK antibody-dependent cell-mediated cytotoxicity (ADCC), appear to be involved in the immunological control of virus infections, including HCMV. In some cases, their contribution requires epistatic interaction with other genes of the immune system, such as HLA. In the present report, with the aim to gain insight into the immune mechanisms controlling HCMV, we have studied t…

0301 basic medicineHuman cytomegalovirusGenotypeImmunologyPopulationCytomegalovirusPilot ProjectsHuman leukocyte antigenBiologyCohort Studies03 medical and health sciences0302 clinical medicineImmune systemReceptors KIRHLA Antigenskiller immunoglobulin-like receptormedicineImmunology and AllergyHumanshuman cytomegalovirueducationSicilySettore MED/04 - Patologia GeneraleAntibody-dependent cell-mediated cytotoxicityeducation.field_of_studynatural killerImmunosenescenceOriginal Articlesmedicine.diseaseVirologyγ markerTransplantationKiller Cells Natural030104 developmental biologyLogistic ModelsantibodieImmunologyCytomegalovirus Infectionsbiology.proteinAntibodyBiomarkershuman leucocyte antigen030215 immunology
researchProduct

NKp46-expressing human gut-resident intraepithelial Vδ1 T cell subpopulation exhibits high antitumor activity against colorectal cancer

2019

γδ T cells account for a large fraction of human intestinal intraepithelial lymphocytes (IELs) endowed with potent anti-tumor activities. However, little is known about their origin, phenotype and clinical relevance in colorectal cancer (CRC). To determine γδ IEL gut-specificity, homing and functions, γδ T cells were purified from human healthy blood, lymph nodes, liver, skin, intestine either disease-free or affected by CRC or generated from thymic precursors. The constitutive expression of NKp46 specifically identifies a new subset of cytotoxic Vδ1 T cells representing the largest fraction of gut-resident IELs. The ontogeny and gut-tropism of NKp46pos/Vδ1 IELs depends both on distinctive …

0301 basic medicineMaleColorectal cancerImmunotherapy AdoptiveMice0302 clinical medicineSex Hormone-Binding GlobulinCytotoxic T cellAntigens LyIntestinal MucosaIntraepithelial LymphocytesInnate immunityAged 80 and overGastroenterologyAge FactorsReceptors Antigen T-Cell gamma-deltaGeneral MedicineMiddle AgedPhenotypemedicine.anatomical_structure030220 oncology & carcinogenesisDisease ProgressionFemaleColorectal NeoplasmsResearch ArticleAdultColonT cellImmunologyT cellsBiologydigestive systemColorectal cancer; Gastroenterology; Immunology; Innate immunity; T cells03 medical and health sciencesYoung AdultIleummedicineAnimalsHumansAgedNeoplasm StagingTumor microenvironmentInnate immune systemNatural Cytotoxicity Triggering Receptor 1medicine.diseaseColorectal cancer030104 developmental biologyCancer researchIntraepithelial lymphocyteHoming (hematopoietic)T-Lymphocytes Cytotoxic
researchProduct

Release of copper-amended particles from micronized copper-pressure-treated wood during mechanical abrasion

2016

Background We investigated the particles released due to abrasion of wood surfaces pressure-treated with micronized copper azole (MCA) wood preservative and we gathered preliminary data on its in vitro cytotoxicity for lung cells. The data were compared with particles released after abrasion of untreated, water (0% MCA)-pressure-treated, chromated copper (CC)-pressure-treated wood, and varnished wood. Size, morphology, and composition of the released particles were analyzed. Results Our results indicate that the abrasion of MCA-pressure-treated wood does not cause an additional release of nanoparticles from the unreacted copper (Cu) carbonate nanoparticles from of the MCA formulation. Howev…

0301 basic medicinePreservativeCopper particlesAbrasion (mechanical)Cell SurvivalCytotoxicityIn vitro cytotoxicityBiomedical EngineeringNanoparticlechemistry.chemical_elementMedicine (miscellaneous)Pharmaceutical ScienceBioengineering010501 environmental sciences01 natural sciencesApplied Microbiology and BiotechnologyMass SpectrometryCell LineExposure03 medical and health sciencesPressureHumansCytotoxicity0105 earth and related environmental sciencesChemistryResearchtechnology industry and agricultureWaterCytotoxicity; Copper particles; Debris; Exposure; Inhalation; Wood dustMechanical abrasionCopperWood030104 developmental biologyInhalationA549 CellsMolecular MedicineNanoparticlesComposition (visual arts)DebrisReactive Oxygen SpeciesCopperWood dustNuclear chemistry
researchProduct

Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma

2018

Multiple myeloma (MM) is a bone marrow plasma cell neoplasm and is the second most-common hematologic malignancy. Despite advances in therapy, MM remains largely incurable. Elotuzumab is a humanized IgG1 monoclonal antibody targeting SLAMF7, which is highly expressed on myeloma cells, and the antibody is approved for the treatment of relapsed and/or refractory (RR) MM in combination with lenalidomide and dexamethasone. Elotuzumab can stimulate robust antibody-dependent cellular cytotoxicity (ADCC) through engaging with FcγRIIIA (CD16) on NK cells and antibody-dependent cellular phagocytosis (ADCP) by macrophages. Interestingly, SLAMF7 is also expressed on cytolytic NK cells, which also expr…

0301 basic medicineReviewNK cellsLymphocyte ActivationDexamethasoneMice0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsImmunology and AllergyElotuzumabLenalidomideMultiple myelomaAntibody-dependent cell-mediated cytotoxicityBortezomibSLAMF7ADCPPlasma cell neoplasmelotuzumab3. Good healthmultiple myelomaKiller Cells Naturalmedicine.anatomical_structureNK Cell Lectin-Like Receptor Subfamily K030220 oncology & carcinogenesisSLAMF7ADCCmedicine.druglcsh:Immunologic diseases. AllergyImmunologyPlasma CellsAntineoplastic AgentsmacrophageAntibodies Monoclonal HumanizedGPI-Linked Proteins03 medical and health sciencesPhagocytosisSignaling Lymphocytic Activation Molecule FamilymedicineBiomarkers TumorAnimalsHumansbusiness.industryNatural Cytotoxicity Triggering Receptor 1MacrophagesReceptors IgGNKG2Dmedicine.disease030104 developmental biologyCancer researchBone marrowbusinesslcsh:RC581-607Transcription FactorsFrontiers in Immunology
researchProduct

Biological Effect of a Hybrid Anticancer Agent Based on Kinase and Histone Deacetylase Inhibitors on Triple-Negative (MDA-MB231) Breast Cancer Cells

2016

We examined the effects of the histone deacetylase inhibitor (HDACi) suberoylanilide\ud hydroxamic acid (SAHA) combined with the vascular endothelial growth factor receptor-1/2 inhibitor\ud (3Z)-5-hydroxy-3-(1H-pyrrol-2-ylmethylidene)-2,3-dihydro-1H-indol-2-one on MDA-MB-231 breast\ud cancer cells (triple-negative) in the form of both a cocktail of the separate compounds and a chemically\ud synthesized hybrid (N-hydroxy-N'-[(3Z)-2-oxo-3-(1H-pyrrol-2-ylmethylidene)-2,3-dihydro-1H-indol-\ud 5-yl]octanediamide). Comparative flow cytometric and Western blot analyses were performed on\ud cocktail- and hybrid-treated cells to evaluate cell cycle distribution, autophagy/apoptosis modulation,\ud an…

0301 basic medicineVascular Endothelial Growth Factor AIndolesCytotoxicityTriple Negative Breast Neoplasmsbreast cancer; MDA-MB231 cells; histone deacetylase inhibitor; vascular endothelial growth factor receptor-2 inhibitor; cytotoxicity; cell cycle; apoptosis; autophagy; mitochondrial metabolismHydroxamic AcidsCatalysi0302 clinical medicineBreast cancerTumor Cells CulturedCytotoxic T cellSettore BIO/06 - Anatomia Comparata E CitologiaSpectroscopyVorinostatVascular endothelial growth factor receptor-2 inhibitorApoptosis; Autophagy; Breast cancer; Cell cycle; Cytotoxicity; Histone deacetylase inhibitor; MDA-MB231 cells; Mitochondrial metabolism; Vascular endothelial growth factor receptor-2 inhibitor; Catalysis; Molecular Biology; Spectroscopy; Computer Science Applications1707 Computer Vision and Pattern Recognition; Physical and Theoretical Chemistry; Organic Chemistry; Inorganic ChemistryKinaseHistone deacetylase inhibitorapoptosisComputer Science Applications1707 Computer Vision and Pattern RecognitionGeneral MedicineCell cycleFlow CytometryComputer Science ApplicationsCell biologyMDA-MB231 cell030220 oncology & carcinogenesisFemaleQD0241Programmed cell deathmedicine.drug_classCell SurvivalBlotting WesternAntineoplastic AgentsBiologyCell cycleCatalysisArticleInorganic Chemistry03 medical and health sciencesmedicineAutophagyHumansPhysical and Theoretical ChemistryProtein Kinase InhibitorsMolecular BiologyQD0415Histone deacetylase inhibitorAutophagyOrganic ChemistryApoptosiHistone Deacetylase Inhibitors030104 developmental biologyApoptosisMitochondrial metabolismMDA-MB231 cellsHistone deacetylaseInternational Journal of Molecular Sciences; Volume 17; Issue 8; Pages: 1235
researchProduct

Characterization of zolbetuximab in pancreatic cancer models

2018

ABSTRACT In healthy tissue, the tight junction protein Claudin 18.2 (CLDN18.2) is present only in the gastric mucosa. Upon malignant transformation of gastric epithelial tissue, perturbations in cell polarity lead to cell surface exposure of CLDN18.2 epitopes. Moreover, CLDN18.2 is aberrantly expressed in malignancies of several other organs, such as pancreatic cancer (PC). A monoclonal antibody, zolbetuximab (formerly known as IMAB362), has been generated against CLDN18.2. In a phase 2 clinical trial (FAST: NCT01630083), zolbetuximab in conjunction with chemotherapy prolonged overall and progression-free survival over chemotherapy alone and improved quality of life. In this study, the mech…

0301 basic medicinelcsh:Immunologic diseases. AllergyImmunologyCellclaudin 18.2pancreatic cancerlcsh:RC254-282Malignant transformation03 medical and health sciences0302 clinical medicinePancreatic cancermedicineImmunology and AllergyCytotoxicitycomplement-dependent cytotoxicityOriginal ResearchAntibody-dependent cell-mediated cytotoxicityChemistryimab362medicine.diseasetargeted therapylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensComplement-dependent cytotoxicity030104 developmental biologymedicine.anatomical_structureOncologyadccCell culturemonoclonal antibody030220 oncology & carcinogenesisCancer researchimmunotherapyzolbetuximablcsh:RC581-607Ex vivoantibody-dependent cellular cytotoxicityOncoImmunology
researchProduct